Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply with High Purity and Stable Quality Name: Fulvestrant CAS: 129453-61-8 Fulvestrant is used in the treatment of hormone-sensitive advanced breast cancer in postmenopausal women. API High Quality, Commercial Production| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification | By IR, HPLC |
| Specific Optical Rotation | +108.0° to +115.0° |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| 6-Keto-Fulvestrant | ≤0.10% |
| 6,7-Fulvestrant | ≤0.10% |
| Fulvestrant Sulfone | ≤0.20% |
| Fulvestrant Extended | ≤0.30% |
| Fulvestrant Sterol Dimmer | ≤0.80% |
| Any Individual Unspecified Impurity | ≤0.10% |
| Total Impurities | ≤1.0% |
| Fulvestrant A | 42.0%~48.0% |
| Fulvestrant B | 52.0%~58.0% |
| DMF | ≤620ppm |
| Heavy Metals | ≤10ppm |
| Assay | 97.0%~102.0% (on dried basis) |
| Storage | Preserve in well-closed light-resistant containers store refrigerated at 2~8℃ |
| Test Standard | United States Pharmacopoeia (USP) Standard |
| Usage | Estrogen Receptor Antagonist |
Description:
Specifications:
Package & Storage:
| Chemical Name | Fulvestrant |
| Synonyms | (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluorpentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3,17-diol; ICI 182780 |
| CAS Number | 129453-61-8 |
| CAT Number | RF-API81 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C32H47F5O3S |
| Molecular Weight | 606.77 |
| Melting Point | 104.0~106.0℃ |
| Solubility | Soluble in Methanol, Ethanol; Insoluble in Water |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Fulvestrant (ICI-182780) CAS 129453-61-8, is a muscle injection drug developed by the company AstraZeneca and is used in the treatment of hormone-sensitive advanced breast cancer in postmenopausal women. Fulvestrant is the only antiestrogen drug that can be widely clinically used following unsuccessful tamoxifen treatment. This drug is a type of endocrine therapy, so it will not cause any adverse effects commonly seen in chemotherapy, giving it relatively good patient compliance. Multiple clinical trials have found that 250mg Fulvestrant is effective and consistently safe as a second line of treatment for advanced breast cancer. Fulvestrant is a synthetic Estrogen Receptor (ER) Antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
